Comparative Pharmacology
Head-to-head clinical analysis: HALAVEN versus KADCYLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALAVEN versus KADCYLA.
HALAVEN vs KADCYLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent